2019

06/05/2019 Guerbet shows its commitment to supporting professionals in the field of interventional imaging with its launch of a specialized website

Villepinte (France), May 6, 2019 – Guerbet, a global specialist in contrast agents and solutions for medical imaging, has announced the launch of its website for interventional radiologists, specializing particularly in the fields of oncology and vascular embolization:...

[more]


06/05/2019 Guerbet commits to supporting women’s health with its launch of a specialized website

Villepinte (France), May 6, 2019 – Guerbet, a global specialist in contrast agents and solutions for medical imaging, has announced the creation of a specialized website for healthcare professionals dedicated to women’s health and in particular to issues relating to the diagnosis and treatment of...

[more]


30/04/2019 ASPIRE 2019, Guerbet involved in Women’s Healthcare!

A major event, the ASPIRE congress brings together international health professionals with interest in reproductive medicine and fertilityOrganization of a symposium “Current & Future Trends of Hysterosalpingography (HSG) in Clinical Practice” on May 4 from 15:00 to 16:30 The 9th Congress of...

[more]


24/04/2019 Guerbet receives CE mark approval for SeQure® and DraKon™ microcatheters for interventional imaging

Villepinte, France, April 24th, 2019 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the upcoming European launch of SeQure® and DraKon™, two novel microcatheters for peripheral embolization procedures. SeQure® and DraKon™...

[more]


18/04/2019 1st quarter 2019 revenue

1st quarter 2019 revenue Year off to a good start: • €197.3 million; +7.7% at current exchange rates• €195.4 million; +6.7% at constant exchange rates Villepinte, 18 April 2019 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is...

[more]


10/04/2019 Guerbet teams will attend IFFS 2019!

The 2019 edition of the IFFS congress (International Federation of Fertility Societies) will be held in Shanghai, China from April 11th to 14th. IFFS stimulates basic and clinical research, disseminates education, and encourages superior clinical care of patients in infertility and...

[more]


26/03/2019 2018 annual results

Growth and EBITDA in line with announced targets › Reported revenue: €789.6 million › Revenue at constant exchange rates: €825.7 million; +2.3%, in line with the guidance given at Capital Markets Day in April 2018 (GEAR 2023 plan) › Reported EBITDA: €110.6 million, also in line with the...

[more]


Displaying results 1 to 7 out of 9
<< First < Previous 1-7 8-9 Next > Last >>